Little is known about opioid prescribing among individuals who have survived cancer. Our aim is to examine a predominantly socio-economically disadvantaged population for differences in opioid prescribing rates among cancer survivors compared with matched controls without a prior diagnosis of cancer. METHODS: This was a retrospective population-wide matched cohort study. Starting in 2010, individuals residing in Ontario, Canada, who were 18 to 64 years of age and at least 5 years past their cancer diagnosis were matched to controls without a prior cancer diagnosis based on sex and calendar year of birth. Follow-up was terminated at any indication of cancer recurrence, second malignancy, or new cancer diagnosis. To examine the association between survivorship and the rate of opioid prescriptions, an Andersen-Gill recurrent event regression model was implemented, adjusting for numerous individual-level characteristics and also accounting for the matched design. RESULTS: The rate of opioid prescribing was 1.22 times higher among survivors than among their corresponding matched controls (adjusted relative rate, 1.22; 95% CI, 1.11-1.34). Individuals from lower income quintiles who were younger, were from rural neighborhoods, and had more comorbidities had significantly higher prescribing rates. Sex was not associated with prescribing rates. This increased rate of opioid prescribing was also seen among survivors who were 10 or more years past their cancer diagnosis (compared with their controls). CONCLUSION: This study demonstrates substantially higher opioid prescribing rates among cancer survivors, even long after attaining survivorship. This raises concerns about the diagnosis and management of chronic pain problems among survivors stemming from their cancer diagnosis or treatment. Cancer 2017;123:4286-93.
INTRODUCTION
Relieving moderate to severe pain using opioids is a common part of pain management among patients with cancer. 1 For individuals who survive their cancer, commonly defined as individuals who are at least 5 years postdiagnosis, [2] [3] [4] pain often shifts from being a short-term issue during the acute diagnosis and active treatment phase to a chronic problem that can linger for months or years. 5 Factors that could be associated with pain during survivorship could be type and invasiveness of tumors, modalities of anticancer treatment, comorbid conditions, initial pain management, and other individual characteristics such as race, sex, socioeconomic status, and unemployment. [6] [7] [8] [9] Recurrence of cancer or second malignancies may also be reasons for experiencing pain during survivorship.
There are currently no comprehensive estimates on the prevalence of persistent pain in adult cancer survivors. A range of 21% to 41% was estimated as the pain prevalence 1 to 2 years posttreatment, 10 and recent work reported pain prevalence for long-term survivors to be somewhere in the range of 5% to 56%. 11 Studies providing estimates of pain prevalence among survivors should be interpreted with caution; the time at which a pain survey is taken is a critical component, because many treatment-related pains lessen over time as injured tissues heal. 7 Recent research has also compared pain prevalence among survivors of childhood cancer against their siblings. 12 The cumulative incidence of pain sensation and migraine headaches were significantly higher among survivors, although a standardized measure was not used to assess pain. Compared with siblings, survivors of childhood cancer also experienced a higher prevalence of psychoactive medication use, based on self-reported medication use. 13 Patients surviving cancer typically experience a shift in the use of opioids from the routine prescribing that occurred in the active treatment phase to a more measured and thoughtful approach that occurs when pain is expected to persist for years. 7 Specifically, chronic pain management for cancer survivors ideally involves a multidisciplinary approach that uses several modalities focused not only on comfort, but also on improved function. [14] [15] [16] [17] A combination of pharmacotherapy with opioids, physical therapy, regular exercise, and psychosocial interventions may be recommended. 7, 13 This more holistic approach is similar to what is recommended for chronic pain management in the general population who have no prior cancer diagnosis, which involves combining opioids with lifestyle activities that enable the individual to be engaged in valuable experiences that make life enjoyable. 17 To our knowledge, there has been no prior research conducted at the individual level that examines differences in opioid prescribing rates among cancer survivors compared with matched controls who have no prior diagnosis of cancer. The primary aim of this study was to examine the association between cancer survivorship and opioid prescribing rates over time in a predominantly socioeconomically disadvantaged population while adjusting for baseline individual-level characteristics. We also examined whether the association was different for survivors who were at least 10 years beyond their cancer diagnosis, compared with survivors who were 5 to 10 years beyond their cancer diagnosis. A recent Canadian study using cross-sectional survey methods reported the prevalence of pain among adults to be 18.9% 18 and, as noted earlier, the prevalence of pain among cancer survivors is unclear and has a large range. Moreover, because we are not aware of how these prevalence estimates will compare in predominantly socio-economically disadvantaged populations, and as the guidelines for managing pain among survivors are similar to the pain management guidelines for individuals with no prior cancer diagnosis, we hypothesized that there would be no difference in opioid prescribing rates between survivors of cancer compared with age/sex-matched individuals without a history of cancer.
SUBJECTS AND METHODS

Study Population and Observation Period
This was a retrospective matched cohort study conducted in Ontario, Canada, in which survivors of cancer (the exposed group) were matched with individuals without a prior cancer diagnosis (the control group), after which each person was followed to determine their opioid prescription rate. To be eligible for cohort inclusion, each individual had to be part of the Ontario Health Insurance Plan and the Ontario Drug Benefits Program (ODB). The Ontario Health Insurance Plan is Ontario's universal health care insurance program, which is essentially available to all Ontario residents. The ODB is Ontario's funded Pharmacare program that is available to residents who are under 65 years of age, provided they are receiving social assistance (disability or welfare) or their prescription costs are high relative to their household income. [19] [20] [21] This population of predominantly socio-economically disadvantaged individuals are an important group to examine. Recent work has stated this population to be at particularly high risk for misuse of opioids and associated harm; however, their analyses did not include any individuals with a prior diagnosis of cancer. 21 At the start of the study period, January 1, 2010, all individuals who were alive, were 18 to 64 years of age, and had a prior diagnosis of cancer were identified from the Ontario Cancer Registry (OCR), which records all incident cases of cancer diagnosed in Ontario. 22 Among them, only individuals who were at least 5 years past their cancer diagnosis date and who had no indication of a cancer recurrence or second malignancy before the study were included in the cohort; these individuals were considered cancer survivors. [2] [3] [4] An individual was considered to have experienced a cancer recurrence or second malignancy before the study if there was evidence of having radiation therapy, chemotherapy, metastatic disease, or initiation of palliative care at least 1 year after their cancer diagnosis. The 5-year survivor mark was used due to our interest in opioid prescriptions and chronic pain; moreover, individuals in Ontario who show no evidence of disease at 5 years from diagnosis are typically discharged from the cancer center and return back to their general practitioner to receive primary care. Each cancer survivor was then 1:1 matched with an individual who had no prior diagnosis of cancer as of the index date (January 1, 2010). Matching was performed based on calendar year of birth (ie, survivors and controls were the same age on the index date) and sex, which were each retrieved from the Registered Persons Database. 23 Individuals were observed from the beginning of the study until the end of the study on December 31, 2012; cancer recurrence; second malignancy; new cancer diagnosis; initiation of palliative care; death; or loss to follow-up, at which point they were censored. Cancer recurrence was determined based on initiation of radiation therapy, chemotherapy, or metastatic disease found in the OCR. This study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board. Datasets were linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences. 
Outcome Definition
The primary outcome for each individual was the rate of opioid prescriptions filled at a pharmacy during the observation period. Because individuals may have obtained multiple opioid prescriptions and because the time between prescriptions may vary, the ODB program database was used to retrieve the dates of each opioid prescription. Original prescriptions that were dispensed and any subsequent refills arising from the prescription were all captured; a subsequent refill was additionally counted and was not combined together with the original prescription. Dose changes received through a prescription, whether increased or decreased, were also captured and counted as an additional prescription. All prescriptions were counted in the same way for survivors and controls. Time to opioid prescription was measured in months, starting from the index date of January 1, 2010. It should be noted that only opioids obtained with a prescription were included in this study. Our data reflect prescriptions that were dispensed and filled at a pharmacy; prescriptions received but not filled were not captured in administrative databases, nor was it possible for us to know whether the dispensed opioids were actually taken.
Main Exposure and Other Covariate Definitions
The main exposure was cancer survivorship, which was a binary variable indicating whether each individual was a cancer survivor or a control. Other covariates included baseline information on age at the index date, sex, socioeconomic status, rurality, community size, and comorbidity. Type of cancer diagnosis and years since cancer diagnosis (as of the index date) were obtained from the OCR and were only available and recorded among survivors. Socio-economic status (SES) was captured through neighborhood median income quintile (by postal code) where the first quintile represented the lowest income group. Rurality, which was also captured by postal code, was recorded as a binary variable representing whether a subject lived in a rural area (versus an urban area) in Ontario. Comorbidity was calculated using the Deyomodification of the Charlson score based on diagnoses coded in the Canadian Institute for Health Information's Discharge Database. 24, 25 A value of 0 is the lowest possible Charlson score-the lower the Charlson score, the healthier the patient.
Statistical Analyses
Descriptive analyses were conducted by comparing the distribution of each baseline characteristic among cancer survivors and matched controls. Categorical variables were summarized as frequencies and percentages, and continuous variables were described using the median and interquartile range. Pearson chi-squared tests were used to assess the relationships between cancer survivorship and categorical covariates, whereas associations between cancer survivorship and continuous covariates were assessed using pooled two sample t tests.
Initial crude analyses were conducted by comparing the opioid prescription rates among cancer survivors with those of the matched controls. For each group, the crude opioid prescription rate was calculated by dividing the total number of opioid prescriptions (numerator of crude rate) by the aggregated follow-up times (denominator of crude rate), after which a relative opioid prescription rate along with a corresponding 95% confidence interval were obtained. We then conducted an individual-level analysis to model the association between cancer survivorship (main exposure) and opioid prescription rates (outcome). Because each subject was able to receive multiple opioid prescriptions over time, we implemented an AndersenGill recurrent event multivariable regression model. [26] [27] [28] The outcome in this model was each individual's prescription rate, which is determined by the number of prescriptions occurring during their period of observation. Unlike the commonly used Poisson regression model that treats rate as a constant outcome, the Andersen-Gill recurrent event regression method models rate as a function of time, which is important because the times between opioid prescriptions for every individual are not equally spaced. This is why the time to each prescription (from index) for every individual is required for the modeling approach. A robust sandwich variance estimation approach was used to account for the matched design. As decided a priori, multivariable regression analyses accounted for all baseline covariates mentioned above. Note that although matching was based on age and sex, because this was a form of exposure-control matching versus case-control matching, we were able to include these covariates in the model.
Stratified analyses were also conducted among cancer survivors (and their corresponding controls) who had their cancer diagnosis 5 to 10 years before their index date and among cancer survivors (and their corresponding controls) who had their cancer diagnosis 10 or more years before their index date; stratified analyses were additionally done by type of cancer. In each recurrent event regression model, a robust variance estimation approach was used to account for multiple opioid prescriptions from the same individual, and the Breslow method was used to handle ties in prescription times across subjects. 26, 29 Nonparametric analyses examining the difference in opioid prescription rates between survivors and matched controls were performed by estimating mean cumulative functions for both exposure groups over time. 30, 31 The mean cumulative function provides the mean cumulative number of opioid prescriptions over time. This function was estimated with corresponding 95% confidence bands for cancer survivors and controls, and both functions were visually displayed together.
We also descriptively examined the association between survivorship and types of opioid prescriptions. The majority of opioid prescriptions captured in this study can be categorized by the following 5 types: 1) long acting oxycodone (older and newer formulations); 2) transdermal fentanyl; 3) other long-acting opioids (eg, long-acting morphine, long-acting hydromorphone); 4) immediate-release single agents (eg, morphine, hydromorphone); and 5) immediate-release combination agents (which contain an immediate-release opioid and one of either acetaminophen or acetylsalicyclic). 21 Only oral and transdermal formulations were included. In a crosssectional manner, we calculated the crude (unadjusted) rate of prescriptions (per 1000 person-years) for each of these 5 types of opioids during the study period and compared them among survivors against those without a prior cancer diagnosis. Statistical analyses were performed using R 3.1.0. 32 Variables with P values less than .05 were considered to be significant.
RESULTS
A total of 17,202 individuals were included in the study. Among them, 8601 individuals had survived at least 5 years beyond their date of cancer diagnosis and had no indication of experiencing a cancer recurrence before the start of the study. The remaining 8601 individuals were corresponding age/sex-matched controls who had no prior diagnosis of cancer. A description of the baseline characteristics among survivors and controls is provided in Table 1 . Among cancer survivors, the median time since diagnosis was 10 years with an interquartile range of 7 to 16 years. Other than the matched variables (age and sex), the distributions of the remaining characteristics (SES, rurality, and level of comorbidity) were statistically different between survivors and controls. Table 2 provides the crude rate of opioid prescribing, calculated as the total number of opioid scripts divided by the total follow-up time. The crude rate of opioid prescriptions for cancer survivors was significantly higher than that of the matched controls (crude relative rate, 1.220; 95% confidence interval, 1.209-1.232).
Results from the Andersen-Gill recurrent event regression model are provided in Table 3 . After multivariable adjustment, the rate of opioid prescribing was 1.22 times higher among survivors than among the corresponding matched controls (relative rate, 1.219; 95% confidence interval, 1.11-1.33). Individuals who were younger, from rural neighborhoods, and with more comorbidities had significantly higher prescribing rates. Sex was not associated with rates of opioid prescribing. There was also a notable trend in the association between socioeconomic status and opioid prescribing rates, where the rates were significantly higher among individuals from lower income quintiles compared with the wealthiest income quintile. It should be noted that our results reflect the associations that are present in a population of predominantly socio-economically disadvantaged individuals.
The adjusted relative rate of opioid prescriptions (survivors against corresponding controls) stratified by type of cancer diagnosis is provided in Table 4 . Survivors who experienced a prior diagnosis of lung, gynecological, other gastrointestinal, or other genitourinary cancer had significantly higher rates of opioid prescribing compared with their matched controls. Survivors who had a prior diagnosis of any of the remaining cancer types were not statistically different in their opioid prescription rates compared with their matched controls. Table 5 presents the relative rate of opioid prescribing (survivors against corresponding controls), stratified by survivors who were 5 to 10 years past their cancer diagnosis and by survivors who were 10 or more years past their cancer diagnosis. In both groups, the rate of opioid prescribing was significantly higher among survivors compared with their matched controls.
For the purpose of data visualization, Figure 1 plots the estimated mean cumulative number of opioid prescriptions over time (and 95% confidence intervals) for cancer survivors and matched controls. The message from the estimated mean cumulative function is consistent with the message obtained from the multivariable regression models. The figure illustrates that, at any given time since index, the mean cumulative number of opioid prescriptions was significantly higher for survivors compared with controls, and this trend remained consistent over time. By the end of the 36-month period, the mean cumulative number of opioid prescriptions filled by survivors is 7.7, whereas the mean cumulative number of opioid prescriptions filled by controls is 6.3 (comparison P < .0001). Based on the cross-sectional descriptive work examining the association between survivorship and types of opioid prescriptions, there was no significant association between survivorship and the prescription rate of immediaterelease combination agents. However, for each of the remaining 4 types of opioid therapies, the crude rate of prescriptions was significantly higher among survivors of cancer compared with individuals without a prior cancer diagnosis (data not shown).
DISCUSSION
This study demonstrates that the rate of opioid prescribing was significantly higher among survivors of cancer compared with age/sex-matched controls without a prior cancer diagnosis. It should be noted that all survivors were free of cancer recurrence or second malignancy (and all corresponding controls were free of cancer) during their period of follow-up. A higher prescribing rate persisted, even for survivors who were 10 or more years past their cancer diagnosis. Upon stratifying by type of cancer diagnosis, survivors with a prior diagnosis of breast cancer had a similar opioid prescribing rate as their matched controls; however, the rate of prescriptions was greater for survivors of lung, gastrointestinal, genitourinary, or gynecological cancer compared with their corresponding controls. Our findings suggest one or a combination of several possibilities. The prevalence of chronic pain among survivors may be higher, and may remain higher over time compared with the prevalence of chronic pain in the general population with no history of cancer. Prior research has shown indication of this among survivors of childhood cancer, who were found to have a significantly higher prevalence of pain compared with their siblings without a previous cancer diagnosis. 12 Survivors may experience long-term sequelae related to their diagnosis or treatment that cause persistent pain. 33 As survivors become older, other reasons for chronic pain such as osteoarthritis become more likely. It is also possible that a higher rate of opioid prescribing among survivors is due to a dependency that originated from opioid use earlier in the disease trajectory. 34 It is common for cancer patients who have survived more than 5 years without a recurrence to be discharged from the oncology clinic. This raises further concerns about the diagnosis and management of chronic pain problems among survivors stemming from their cancer diagnosis or treatment. Primary care providers who treat cancer survivors should be encouraged to critically examine reasons for lingering opioid use among their patients. Not only can chronic opioid therapy negatively affect the immune system, it can give rise to various health problems such as endocrinopathies, osteoporosis, neurological or cardiopulmonary effects, and also result in a higher likelihood of abuse and addiction. Specialized teams offering an integrative perspective may be important for the management of chronic pain among cancer survivors.
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This study had numerous strengths. It was a population-wide cohort study analyzed longitudinally at the individual level. It consisted of a matched 1:1 exposure-control study design, a desirable feature that allowed for characteristics among survivors and controls to be similar from baseline. Individual follow-up was terminated at any indication of cancer recurrence, thus ensuring that opioid rates were captured only during cancer-free periods of observation. The analytic method was rigorous and well-suited for the longitudinal structure of the data; it was able to handle opioid prescriptions as a repeated outcome. However, the results of the study must be interpreted in light of several limitations. The administrative drug data were only available from individuals who were eligible for the Ontario Drug Benefit program; these eligible individuals represented only a portion of the province's population under 65 years of age, and that the majority of these persons were economically disadvantaged. All inferences being made from the results of our work are specific to this population, and generalizability may be limited to the remaining population. Due to the requirements for ODB enrollment, which include individuals with high prescription costs (relative to their household income), there are notable proportions of survivors and controls in our cohort with high SES (for example, 31.6% of survivors and 29.1% of controls reside in the 2 highest income quintiles). As a result, the magnitude in the association between SES and opioid prescription rates, and the trend in association as SES varies, are still important points to bring forward. Although we adjusted for several well-known confounding variables, there may be other confounders that could not be measured, including individual preferences and barriers to opioid use. Moreover, only opioids obtained with a prescription are included in this study. Our data reflect prescriptions dispensed/filled at a pharmacy; prescriptions received but not filled were not captured in administrative databases, nor was it possible for us to know if the dispensed opioids were actually taken.
In conclusion, this large Ontario-wide cohort study shows that survivors of cancer have higher opioid prescription rates compared with matched controls without a prior cancer diagnosis, and this trend persists even for survivors who are 10 or more years past their cancer diagnosis. Further work is required to understand why this is the case. Physicians providing primary care to cancer survivors should consider close examination of reasons for continued opioid use in order to differentiate chronic pain from dependency, as well as explore alternative methods for pain control, such as physical therapy, exercise, and acupuncture. 7, 13 Our study emphasizes the need for survivors of cancer to be cared for by providers that are able to give supportive cancer care and are experienced in holistic approaches for managing chronic pain.
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